| Previous Close | 21.45 |
| Open | 21.50 |
| Volume | 19,619,585 |
| Avg. Volume (3M) | 61,171,192 |
| Market Cap | 48,870,813,696 |
| Price / Earnings (TTM) | 22.31 |
| Price / Earnings (Forward) | 25.51 |
| Price / Sales | 7.58 |
| Price / Book | 4.02 |
| 52 Weeks Range | |
| Earnings Date | 20 Aug 2025 - 25 Aug 2025 |
| TTM Dividend Yield | 0.82% |
| Profit Margin | 22.95% |
| Operating Margin (TTM) | 23.60% |
| Diluted EPS (TTM) | 0.930 |
| Quarterly Revenue Growth (YOY) | 17.00% |
| Quarterly Earnings Growth (YOY) | 75.90% |
| Total Debt/Equity (MRQ) | 19.71% |
| Current Ratio (MRQ) | 1.71 |
| Operating Cash Flow (TTM) | 3.20 B |
| Levered Free Cash Flow (TTM) | 1.54 B |
| Return on Assets (TTM) | 6.82% |
| Return on Equity (TTM) | 12.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | 3SBIO | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.25 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| 3SBIO | 49 B | 0.82% | 22.31 | 4.02 |
| KEYMED BIO-B | 12 B | - | - | 6.29 |
| HAOHAI BIOTEC | 12 B | 3.41% | 13.63 | 0.970 |
| ASCLETIS-B | 9 B | - | - | 5.23 |
| INNOVENT BIO | 167 B | - | 132.16 | 10.62 |
| AKESO | 138 B | - | - | 18.31 |
|
3SBio Inc is a biotechnology company. As a pioneer in the Chinese biotechnology industry, the Group has extensive expertise in researching, developing, manufacturing, and marketing biopharmaceuticals. The core products of the Group include several biopharmaceutical drugs, TPIAO recombinant human erythropoietin rhEPO products EPIAO and SEPO, Yisaipu, Cipterbin, and a small molecule drug, Mandi. Except for minoxidil, an over-the-counter drug, the others are all older-generation biologics. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Value |
| % Held by Insiders | 27.05% |
| % Held by Institutions | 23.31% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |